Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    19303137 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Conditions: Gastrointestinal Stromal Tumors;   KIT +;   Resected Gastrointestinal Stromal Tumors;   Non-metastatic;   High Risk of Recurrence
Intervention: Drug: Imatinib maintenance
2 Completed Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Other: placebo;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years